Recombinant factor concentrates may increase inhibitor development: a single centre cohort study
Author:
Publisher
Wiley
Subject
Genetics(clinical),Hematology,General Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2516.2010.02464.x/fullpdf
Reference30 articles.
1. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy;Fischer;Haemophilia,2001
2. Twenty-five years’ experience of prophylactic treatment in severe hemophilia A and B;Nilsson;J Intern Med,1992
3. Inhibitor incidence with recombinant vs. Plasma-derived FVIII in previously untreated patients with severe hemophilia A: homogenous results from for published observational studies;Calvez;J Thromb Haemost,2008
4. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A;Chalmers;Haemophilia,2007
5. Comparison of high responder inhibitor frequency in recent studies of previously untreated patients with hemophilia A;Ehrlich;Thromb Haemost,1998
Cited by 28 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Perioperative management of patients with hemostatic system disorders. Methodological recommendations of the All-Russian public organization “Federation of Anesthesiologists and Reanimatologists” and the National Association of Specialists in Thrombosis, Clinical Hemostasiology and Hemorheology;Annals of Critical Care;2024-01-27
2. Hemophilia a patients with inhibitors: Mechanistic insights and novel therapeutic implications;Frontiers in Immunology;2022-12-08
3. The Impact of Recombinant Versus Plasma-Derived Factor VIII Concentrates on Inhibitor Development in Previously Untreated Patients With Hemophilia A: A 2021 Update of a Systematic Review and Meta-Analysis;Cureus;2022-06-16
4. Epidemiological Challenges in Rare Bleeding Disorders: FVIII Inhibitor Incidence in Haemophilia A Patients—A Known Issue of Unknown Origin;International Journal of Environmental Research and Public Health;2020-12-30
5. Safety of recombinant coagulation factors in treating hemophilia;Expert Opinion on Drug Safety;2019-02-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3